Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 151 entries
View as:

A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT06657378 Org: User:
Start: 11/18/24 End: 06/15/28 Due: 06/15/29

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02579616 Org: User:
Start: 10/23/15 End: 02/27/19 Due: 02/27/20

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00832819 Org: User:
Start: 02/28/09 End: 10/31/11 Due: 10/31/12

A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05278676 Org: User:
Start: 07/01/22 End: 12/13/22 Due: 12/13/23

Phase 1 Study of E7090 in Subjects With Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT02275910 Org: User:
Start: 10/28/14 End: 09/03/21 Due: 09/03/22

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01432886 Org: User:
Start: 10/31/11 End: 12/31/13 Due: 12/31/14

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01401530 Org: User:
Start: 07/31/11 End: 01/31/16 Due: 01/31/17

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03006926 Org: User:
Start: 02/13/17 End: 11/22/22 Due: 11/22/23

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02676778 Org: User:
Start: 03/28/16 End: 04/26/19 Due: 04/26/20

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02427607 Org: User:
Start: 05/12/15 End: 11/09/16 Due: 11/09/17

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02094729 Org: User:
Start: 09/30/13 End: 05/31/15 Due: 05/31/16

A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Phase: N/A Priority: Normal
NCT ID: NCT02225288 Org: User:
Start: 09/30/14 End: 02/28/15 Due: 02/28/16

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01728623 Org: User:
Start: 09/03/12 End: 10/01/15 Due: 10/01/16

A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00921869 Org: User:
Start: 10/31/09 End: 06/30/11 Due: 06/30/12

Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02300506 Org: User:
Start: 01/10/14 End: 07/10/16 Due: 07/10/17

E2022 Patch Formulation Multiple Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT01450839 Org: User:
Start: 09/30/11 End: 02/29/12 Due: 02/28/13

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

Phase: N/A Priority: Normal
NCT ID: NCT02371174 Org: User:
Start: 09/03/14 End: 01/21/18 Due: 01/21/19

Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study

Phase: N/A Priority: Normal
NCT ID: NCT01645800 Org: User:
Start: 08/31/12 End: 03/31/15 Due: 03/31/16

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04078295 Org: User:
Start: 09/05/19 End: 03/31/26 Due: 03/31/27

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Phase: N/A Priority: Normal
NCT ID: NCT02452684 Org: User:
Start: 10/01/12 End: 12/22/15 Due: 12/22/16

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT02953743 Org: User:
Start: 09/01/16 End: 12/28/20 Due: 12/28/21

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Phase: N/A Priority: Normal
NCT ID: NCT01731275 Org: User:
Start: 08/31/12 End: 08/31/13 Due: 08/31/14

Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis

Phase: N/A Priority: Normal
NCT ID: NCT00165776 Org: User:
Start: 06/30/04 End: 11/30/06 Due: 11/30/07

A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT04609852 Org: User:
Start: 10/28/20 End: 08/18/23 Due: 08/18/24

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT03058406 Org: User:
Start: 03/01/16 End: 11/04/18 Due: 11/04/19